How does glyburide work
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest glyburide works by stimulating insulin release, inhibiting non-enzymatic glycation, reducing brain swelling in specific conditions, and affecting calcium and potassium levels, while also having complex pharmacokinetics and potential drug interactions.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Mechanism of Action of Glyburide
Glyburide and Sulfonylurea Receptors
Glyburide, also known as glibenclamide, is a second-generation sulfonylurea drug primarily used to manage type 2 diabetes. It functions by inhibiting the sulfonylurea receptor 1 (Sur1) at nanomolar concentrations, which is part of the KATP (Sur1–Kir6.2) channels in pancreatic beta cells. This inhibition leads to the closure of these potassium channels, resulting in cell depolarization and subsequent opening of voltage-dependent calcium channels. The influx of calcium ions into the cells stimulates the release of insulin, thereby lowering blood glucose levels .
Glyburide and Calcium Dynamics
Glyburide significantly impacts intracellular calcium concentrations. In pancreatic islet cells, glyburide increases cytosolic-free calcium concentrations ([Ca2+]i) in a dose-dependent manner. This increase is facilitated by promoting calcium influx through voltage-dependent calcium channels and mobilizing intracellular calcium stores. The rise in [Ca2+]i is crucial for the stimulation of insulin secretion, both in the presence and absence of extracellular calcium.
Glyburide and Insulin Gene Expression
Glyburide not only stimulates insulin release but also enhances insulin gene expression. It increases the preproinsulin (PPI) mRNA levels in isolated rat islets, indicating an upregulation of insulin synthesis. This process involves protein kinase C (PKC) and cyclic nucleotide-dependent protein kinases, which mediate the effects of glyburide on insulin release and gene expression.
Glyburide and Advanced Glycation Endproducts (AGEs)
Glyburide exhibits antiglycation properties, which are beneficial in managing diabetic complications associated with advanced glycation endproducts (AGEs). It inhibits the formation of AGEs by interacting with human serum albumin (HSA) and reducing free lysine modification. This interaction is entropically favorable and spontaneous, contributing to the stability of the glyburide-HSA complex. The antiglycation activity of glyburide helps improve biochemical markers such as free thiol groups and carbonyl content, thereby mitigating the adverse effects of AGEs.
Glyburide in Cerebral Edema and Stroke
Glyburide has been repurposed for use in acute central nervous system injuries, particularly in managing cerebral edema following large hemispheric infarction. It targets the Sur1–transient receptor potential melastatin 4 (Trpm4) channels, which are upregulated in the neurovascular unit after ischemia. By blocking these channels, glyburide reduces brain swelling and improves functional outcomes in stroke patients. Clinical trials have shown promising results in reducing brain swelling, midline shift, and mortality in patients treated with intravenous glyburide.
Glyburide and Cardiac Effects
Glyburide also affects cardiac function by blocking ATP-sensitive potassium (KATP) channels. This blockade can reduce the rise in extracellular potassium levels and intramyocardial conduction delay during myocardial ischemia, potentially attenuating the electrophysiologic consequences that lead to malignant ventricular arrhythmias. However, glyburide has been associated with an increase in QT dispersion, which may elevate the risk of arrhythmias and sudden cardiac death .
Pharmacokinetics and Drug Interactions
Glyburide is metabolized by the liver and excreted equally through biliary and renal routes. It has a high affinity for serum albumin, with 99% of the drug being protein-bound. Glyburide's pharmacokinetics can be influenced by cytochrome P450 2C9 (CYP2C9) polymorphisms, which affect its metabolism and the resultant insulin and glucose responses. Additionally, glyburide can inhibit CYP2C9 and CYP3A4, leading to potential drug-drug interactions when coadministered with other medications metabolized by these enzymes .
Conclusion
Glyburide is a potent sulfonylurea drug that lowers blood glucose levels by stimulating insulin release through the inhibition of KATP channels and increasing intracellular calcium concentrations. It also enhances insulin gene expression and exhibits antiglycation properties, which are beneficial in managing diabetic complications. Beyond its use in diabetes, glyburide has shown promise in treating cerebral edema and reducing the risk of ischemia-induced arrhythmias. However, its effects on cardiac function and potential drug interactions necessitate careful monitoring in clinical use.
Sources and full results
Most relevant research papers on this topic
